NCT01269385 2020-06-23
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 1/2 Completed
Clinical Trials
1 trialsPhase 1/2 × Leukemia, Lymphocytic, Chronic, B-Cell × Amplified Fragment Length Polymorphism Analysis × Clear all